Maze Therapeutics initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Maze Therapeutics (MAZE) with an Overweight rating and $30 price target The company’s Compass platform has produced multiple shots on goal to date, the analyst tells investors in a research note. The firm views the MZE829 approach in in APOL1 kidney disease as “de-risked,” from a mechanistic perspective via the mid-stage data from competitor Vertex’s inaxaplin. JPMorgan believes MZE829 “provides multiple potential ways to win” for Maze.